fda approved ghk-cu injection is I hear it all the time — “GHK-Cu isn't GHK-Cu Topical: Evidence, Safety &

(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)

Most peptides undergo rapid enzymatic degradation by gastric pepsin, pancreatic proteases, and intestinal brush border peptidases, resulting in negligible oral bioavailability

doi: 10.2147/jir.S219586 59 WieseMDManning-BennettATAbuhelwaAY

DSIP Ships from Canada